|Articles|January 5, 2021

US Nearing 350,000 Daily COVID-19 Vaccine Doses

In the first week of 2021, the US is currently leading all countries in total vaccine administrations, despite state-level distribution setbacks.

As of Monday, the United States has administered more than 4.5 million doses of coronavirus 2019 (COVID-19) vaccine to its population, per estimated counts from the US Centers for Disease Control and Prevention (CDC) and University of Oxford.

While discussion surrounding the distribution of recently-authorized two-dose mRNA vaccines BNT162b2 from Pfizer and BioNTech, and mRNA-1273 from Moderna, has focused on the merits of single-dose versus standard administration, the nation has increased its daily vaccination count from approximately 235,000 to 348,000 in just one week.

Presently, the very small countries of Israel and Bahrain are reporting a substantial vaccination count per capita, while the United States improves on a slow rollout start.

United States
4.56 million
1.38 per 100
China
4.5 million
0.31 per 100
Israel
1.22 million
14.14 per 100
United Kingdom
944,539
1.39 per 100
Russia
800,000
0.55 per 100
Germany
265,610
0.32 per 100
Italy
128,880
0.21 per 100
Canada
117,768
0.31 per 100
Spain
82,834
0.18 per 100
Bahrain
61,612
3.62 per 100

Data per Our World in Data (Jan 5, 2021, 12 AM EST)

Unsurprisingly, among the most vaccinated states thus far are California, Texas, and New York—large, highly populated regions notably affected during various waves of the pandemic since March 2020.

California
451,702
1.14 per 100
Texas
374,238
1.29 per 100
New York
274,713
1.41 per 100
Florida
264,512
1.23 per 100
Colorado
262,275
1.95 per 100
Illinois
176,577
1.39 per 100
Pennsylvania
163,207
1.28 per 100
Ohio
159,869
1.37 per 100
Tennessee
152,516
2.23 per 100
Massachusetts
110,279
1.60 per 100

Data per CDC COVID-19 Tracker (Jan 4, 2021, 9 AM EST)

For more information on COVID-19 vaccination research, distribution, and assessment, check out some of these recent Contagion stories:

What More COVID-19 Testing Can Do for 2021

Moderna Vaccine Shows Significant COVID-19 Prevention Efficacy in Phase 3 Data

UK Approves Emergency Authorization for the AstraZeneca and Oxford COVID-19 Vaccine


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.